Kessler Investment Group Buys $5 Million More in Luxury Outerwear Stock, Canada Goose

Kessler Investment Group increased its Canada Goose (GOOS) stake by 379,516 shares (approx. $5.05M based on quarter-average price), bringing its position to 678,892 shares valued at $8.79M and representing 3.7% of the fund's 13F-reportable AUM as its tenth-largest holding. GOOS trades at $11.24 (2/6/26), with TTM revenue of $1.04B and net income of $15.01M; the company reported Q3 sales growth of 14% (North America +20%) and continued DTC growth but missed on margins and earnings, sending the stock down >10% after the print. The article notes a discounted valuation (~1.1x sales, ~9x free cash flow) and frames Kessler's purchases as a potential value accumulation amid cyclicality and recent volatility.

Analysis

Market structure: Kessler’s meaningful buy of GOOS (now 678,892 shares, $8.8M or 3.7% of AUM) signals conviction in luxury outerwear versus mass apparel. Direct beneficiaries include Canada Goose (pricing power via DTC) and upstream suppliers of down/fabrics; fast-fashion and low-margin wholesalers are losers if premium consumers reallocate spend. The trade is unlikely to move rates or FX materially, but expect elevated GOOS options IV around earnings and modest CAD flows if institutional accumulation continues.

Risk assessment: Key tail risks are weather-driven demand shocks, animal-welfare regulatory actions (fur bans) and raw-material cost spikes that could compress margins >200bps. Time horizons diverge: days—earnings-driven 10%+ swings; weeks—sentiment/positioning from 13F updates; quarters—margin recovery and FCF conversion; years—brand equity and channel mix. Hidden dependencies include wholesale partner inventory levels and FX pass-through on retail pricing. Catalysts: next quarter’s gross-margin guidance, holiday trading cadence, and further institutional buys/sells.

Trade implications: Direct play — establish a tactical long in GOOS (ticker GOOS) sized 2–3% of equity risk at market <= $12, add below $9, target $16–18 in 12–18 months, stop-loss $9. Options — buy Jan 19, 2027 GOOS 12.5C LEAPs for asymmetric upside (50–100bp portfolio allocation) and hedge near-term earnings with 3–6 month 10P puts if IV compresses. Pair trade — long GOOS vs short XRT (equal-dollar) 0.5–1.0% notional to isolate brand vs retail cyclicality.

Contrarian angles: Consensus fixates on weak margins; what’s underweighted is durable DTC growth (+4th consecutive quarter) and low valuation (≈1.1x sales, ~9x FCF) implying mean reversion if cost control returns. The market may be overpricing cyclical risk — a disciplined buyer can profit if gross margin rebounds 150–300bps over two quarters. Beware the reverse: persistent margin deterioration or regulatory haircuts would quickly rerate GOOS lower, so hinge positions on quarterly margin inflection and Kessler follow-through.

Key Decisions for Investors

• Establish a 2–3% long equity position in GOOS at market price ≤ $12; add a second tranche if price falls below $9; set a tactical profit target of $16–18 within 12–18 months and a hard stop-loss at $9 (≈-20% from $11.24).
• Purchase Jan 19, 2027 GOOS 12.5C LEAPs equal to ~0.5–1.0% of portfolio for leveraged upside; hedge immediate earnings risk by buying 3–6 month GOOS 10P puts if IV < 40% to cap short-term downside.
• Implement a relative-value pair: long GOOS vs short XRT (equal-dollar exposure) sized 0.5–1.0% notional to isolate brand/demand outperformance; hold 6–12 months and rebalance on any >10% move in either leg.
• Cut or avoid new exposure if next quarterly report shows gross-margin compression >200bps QoQ or sequential DTC sales decline; otherwise add to positions if Kessler increases its stake in the next 13F (monitor next 45–75 days for follow-through).